Management

Daniel O. Wilds was appointed the Company's President and CEO and a Director in August 2003. From 1998 to July 2003, Mr. Wilds served as Chairman, President and CEO of Northwest Biotherapeutics, Inc. Previously, he was President and CEO of Shiloov Biotechnologies (USA), Inc. from 1997 to 1998. From 1992 to 1996, Mr. Wilds was President and CEO of Adeza Biomedical Corporation, prior to which he served as the President and CEO of Medisense, Inc. and President of Baxter's Chemotherapy Service. Mr. Wilds has also served as President and COO of Travenol-Genentech, Inc., a joint venture between Baxter International and Genentech, Inc., and has held other domestic and international senior management positions in the biomedical and biopharmaceutical fields. Mr. Wilds currently serves on the boards of SCOLR Pharma, Inc. and Helix BioMedix, Inc. and was a member of the Leadership Council for the Albert B. Sabine Vaccine Institute's Cancer Vaccine Consortium. Mr. Wilds holds a BA from California State University, Los Angeles and an MBA from Northwestern University.

Alan M. Mitchel was appointed Senior Vice President Business & Legal Affairs and Chief Legal Officer in January 2005.  Mr. Mitchel has extensive legal, business and corporate finance experience.  He most recently served as the Company’s outside legal counsel  at the Seattle law firms of Gray Cary and previously Garvey Schubert Barer.  Mr. Mitchel was the Chief Legal Officer of American Capital Corporation, a financial services holding company based in Miami from 1985 to 1991.  Mr. Mitchel commenced his legal career at Greenberg Traurig, a Miami law firm, where he worked from 1980-1985.  He is a graduate of Duke University School of Law.

Stephen J. Turner has worked for the Company since the fall of 1999 and been responsible for the commercialization and application of the CDT®, controlled delivery technology platform. In the winter of 2003, he was promoted to Vice President, Chief Technical Officer of the Company. In addition to Mr. Turner's involvement in the growth and application of the Company's technology platform, he is named on one recently issued patent, contributed to numerous additional patent filings, has several industry related publications, and has presented his research findings at numerous academic seminars and symposia. Mr. Turner is an active member in scientific organizations including AAPS (American Association of Pharmaceutical Scientists) and the Controlled Release Society. Mr. Turner holds a BS in Biology with a minor in Geochemistry from Western Washington University.

Richard M. Levy was appointed Chief Financial Officer and Vice President of Finance in June  2006, and served as Interim Chief Financial Officer and Vice President of Finance commencing December 15, 2005. Mr. Levy has over twenty-six years of experience in financial institutions as a Chief Financial Officer, Controller, consultant and auditor. He has been the CFO for the Specialty Finance Segment and Corporate Controller for Washington Mutual Bank. Mr. Levy worked for Bank of America for seven years. His experience there included being the Senior Vice President and Controller of the company’s Texas operations and also included coordinating all accounting activities and acting as Chief Financial Officer for new acquisitions, including acquisitions of community banks and the transition process into a larger holding company.  Mr. Levy graduated from the University of California, Santa Barbara in 1980 with a degree in Business Economics and Accounting. He has eight years of audit experience with Ernst & Whinney in San Francisco, California. His public accounting experience has included international operations, litigation support and internal control analysis for local community banks, money center banks, multinational holding companies and other financial institutions.

Board of Directors

Michael N. Taglich was appointed to the Board in August 2003. Mr. Taglich has served as the President and co-founder of Taglich Brothers, Inc., a NASD broker-dealer focused on public and private micro cap companies since 1992. From 1987 - 1992, Mr. Taglich was Vice President at Weatherly Securities. He is a director of Dilon Technologies Inc., Premier Funding, CHF Technologies, and CHB of Boston Ship Acquisition LLC. Mr. Taglich earned a BS from New York University.

Randall L-W. Caudill, D.Phil. has served as a member of the Board since 2002. Dr. Caudill is currently President of Dunsford Hill Capital Partners, a financial consulting firm serving early-stage healthcare and technology companies. From 1987 to 1997, while at Prudential Securities, Dr. Caudill established and headed the firm's San Francisco investment banking practice and served as head of the Mergers and Acquisitions Department and co-head of Prudential's investment banking division. Dr. Caudill also served as executive director and co-head of mergers and acquisitions at Morgan Grenfell Inc. and vice president in the Mergers and Acquisitions Department of The First Boston Corporation. Dr. Caudill currently serves on the boards of VaxGen, Inc., RamGen Inc., and Helix BioMedix Inc. Dr. Caudill received a master's degree in Public and Private Management from Yale University and earned a doctorate of philosophy while a Rhodes Scholar at Oxford University.

Reza Fassihi, Ph.D. joined the Board in November 2003. Dr. Fassihi is the co-inventor and patent holder of three patents in SCOLR's CDT® platform. He is currently Professor of Biopharmaceutics and Industrial Pharmacy at Temple University , School of Pharmacy. Dr. Fassihi joined Temple University in 1992 where he has served as professor, director of graduate programs, has chaired various committees and is Co-Chair of PPF (Philadelphia Pharmaceutical Forum).

Dr. Fassihi is widely published in more than 100 peer-reviewed professional papers, numerous chapters in books and is credited with more than 300 abstracts. Currently he has ongoing projects in collaboration with various pharmaceutical laboratories. He acts as a consultant to a number of pharmaceutical and nutritional manufacturers, government agencies, and has served as an expert witness on issues related to pharmaceutical products. Dr. Fassihi was awarded a gold medal for his research work at Brighton University in England in 1978, where he received his Ph.D. He was assistant professor at the University of Iran, postdoctoral fellow at Brighton University, a Senior Scientist at Welsh School of Pharmacy, Senior Lecturer at Rhodes University in South Africa and Professor and Head of Department, School of Pharmacy, University of Witwatersrand in Johannesburg, where he was awarded with gold medals by both the Academy of Pharmaceutical Sciences of South Africa and the Society of Cosmetic Chemists.

Herbert L. Lucas has been a Director since 1991. He served as President from 1972 to 1981 of Carnation International in Los Angeles and as a director of the Carnation Company. Since 1982, Mr. Lucas has managed his family investment business. He has served on the boards of various financial and business institutions including Wellington Trust Company, Arctic Alaska Fisheries, Inc., and Sunworld International Airways, Inc. Mr. Lucas has served as Trustee of The J. Paul Getty Trust, the Los Angeles County Museum of Art, The Morgan Library, and Winrock International Institute for Agricultural Research and Development. He was formerly a member of the Board of Trustees of Princeton University. Mr. Lucas received a BA degree in History in 1950 from Princeton University and an MBA degree in 1952 from Harvard University Graduate School of Business Administration.

Bruce S. Morra joined the Board in August 2007. Dr. Morra has more than 25 years of pharmaceutical, medical device, drug delivery, biotech and polymers industry leadership experience, and is currently a consultant and Board member to various companies in these fields, including the publicly-traded companies InforMedix Holdings, Inc., and Unigene Laboratories, Inc., and the private company BioPharm Solutions, Inc. From April 2003 through the end of 2004, Dr. Morra was President of West Pharmaceutical Services’ Drug Delivery and Contract Clinical Research businesses. Since 1998 Dr. Morra has been a Board member and advisor for life science and material companies, which included positions as Chief Business Officer for Progenitor Cell Therapy, LLC, a start-up company performing stem cell and other cell therapy process, device and drug contract research and manufacturing from 2002 to 2003; and President, COO and CFO of Biopore Corporation and its sister company Polygenetics, Inc., from 1998 to 2004. From 1993 to 2000 Dr. Morra served as President, COO and Founder of Flamel Technologies, Inc., a drug delivery systems and biomaterials company. Before he started Flamel’s US subsidiary in 1993, Dr. Morra served as the President of ISP Filters, Inc. Dr. Morra earned his Ph.D. and M.S. in Polymer Science and Engineering and his M.B.A. from the University of Massachusetts, Ahmerst in 1980, after graduating magna cum laude in Chemical Engineering from Princeton University in 1976.

Wayne L. Pines joined the Board in April 2004. Mr. Pines is an international consultant on FDA-related regulatory and media issues and on corporate crisis management. Since 1993, he has been President of Regulatory Services and Healthcare at APCO Worldwide, a public affairs firm in Washington, D.C. Prior to that, Mr. Pines was Executive Vice President of Burson-Martseller, an international public relations agency. Mr. Pines served for ten years at the FDA, as Chief of Consumer Education and Information, Chief of Press Relations and Associate Commissioner of Public Affairs. He is also a member of the board of Excel Life Sciences and MyCareTeam.com, and in the non-profit sector is Chairman of the Board of the Medstar Research Institute and President of the Alliance for a Stronger FDA. A frequent lecturer at educational conferences, he has authored or edited a dozen books on FDA-related issues, medical advertising regulation and crisis management. He is a graduate of Rutgers University.

Jeffrey B. Reich, M.D. joined the Board in October 2007. Dr. Reich is Vice President/Senior Healthcare Analyst with Cramer, Rosenthal and McGlynn, an investment firm based in New York City. Previously, Dr. Reich was a principal at Merlin Biomed Group, a New York City-based asset management firm that invests globally in public and private healthcare companies. Dr. Reich is a member of the board of Neurologix, Inc., a development-stage company engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system utilizing gene therapies. He has also served as an assistant professor of clinical neurology at Weill Medical College of Cornell University since 1995. Dr. Reich received his medical degree from Weill Medical College of Cornell University in 1987.

Gregory L. Weaver joined the Board in October 2007. Mr. Weaver has served as Chief Financial Officer of both public and private companies since 1992, and is currently CFO of Talyst, a leader in pharmacy automation products and services, in Bellevue, WA.  Mr. Weaver has been a director and chairman of the audit committee of Clesion Corp. since 2005.  Prior to Talyst, Mr. Weaver most recently served as Senior VP and CFO of Sirna Therapeutics, and RNAI therapeutics company in San Francisco, until the sale of the firm to Merck, Inc. in December 2006.  From 2002 through 2005, Mr. Weaver as CFO of Nastech Pharmaceutical Company, a drug delivery company located in WA.  From 1999 to 2002, Mr. Weaver was CFO of Ilex Oncology, Inc., a cancer drug development company, and from 1996 to 1998 he was the CFO of medical device manufacturer Prism Technologies in Texas.  Previously, Mr. Weaver, a CPA, held increasingly senior positions with Fidelity Capital in Boston and with Harte-Hanks in the publishing industry.  He began his career with Arthur Andersen LLP.  Mr. Weaver earned his MBA from Boston College and B.S. in accounting from Trinity University.